论文部分内容阅读
目的 :探讨 Ki-67抗原在肝外胆管癌组织中的表达及其临床应用价值。方法 :采用免疫组化技术 ( S-P法 )检测 3 5例肝外胆管癌石蜡包埋标本中 Ki-67的表达 ,与 12例慢性胆管炎标本作对照。结果 :肝外胆管癌组织中 Ki-67标记指数 ( Ki-67LI)为 3 4 .6± 19.5 ,显著高于胆管炎组织的 16.3± 12 .8( P<0 .0 1)。 Ki-67LI与肝外胆管癌病理类型无关 ,但在浸润深度 T1 、T3期 ,临床分期 、 期与 、 期及淋巴结转移之间均表现出显著差异。 Ki-67LI与病人术后生存期呈显著负相关 ,Ki-67LI越高 ,病人术后生存期越短 ,预后越差。结论 :Ki-67检测对临床评估肝外胆管癌病情 ,判断病人预后及选择辅助治疗方法有一定的指导意义。
Objective: To investigate the expression of Ki-67 antigen in extrahepatic cholangiocarcinoma and its clinical value. Methods: The expression of Ki-67 in paraffin embedded specimens of 35 cases of extrahepatic cholangiocarcinoma was detected by immunohistochemistry (S-P method) and compared with 12 cases of chronic cholangitis. Results: The Ki-67 labeling index (Ki-67LI) of extrahepatic cholangiocarcinoma was 34.6 ± 19.5, which was significantly higher than that of cholangitis (16.3 ± 12.8, P <0.01). Ki-67LI was not related to the pathological type of extrahepatic cholangiocarcinoma, but showed significant differences in depth of invasion T1, T3, clinical stage, stage, stage and lymph node metastasis. The Ki-67LI was significantly negatively correlated with the postoperative survival of patients, and the higher the Ki-67LI, the shorter the postoperative survival was, the worse the prognosis was. Conclusion: The Ki-67 test has certain guiding significance for the clinical evaluation of the condition of extrahepatic cholangiocarcinoma, the prognosis of patients and the choice of adjuvant therapy.